AnaptysBio - Overview
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Science
Immune Cell Modulation
Listen to Short Takes on Deep Science
Anaptys Publications and Relevant Literature
Pipeline
Overview
ANB032
Rosnilimab
ANB033
ANB101
Imsidolimab
Partnerships
Investors / News
Overview
News
Events
Presentations
Goverance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
Total Rewards Program Highlights
Get to Know Our Team
Join Team Anaptys!
Contact
Toggle
Overview
ANB032
Overview
Atopic Dermatitis
Rosnilimab
Overview
Rheumatoid Arthritis
Ulcerative Colitis
ANB033
ANB101
Imsidolimab
Partnerships
Pipeline
Development Stage and Anticipated Milestones
Antibody
Program
Therapeutic
Indication
Lead Optimization
IND Enabling
Phase 1
Phase 2
Phase 3
Rosnilimab
(PD-1 agonist)
Top-line P2 data
Q1 2026
ANB033
(CD122 antagonist)
Inflammatory Diseases
Ulcerative Colitis
Rheumatoid Arthritis
P1 initiation
Q4 2024
ANB101
(BDCA2 modulator)
Inflammatory Diseases
IND submission
Q4 2024
Top-line P2b data
Q1 2025
Generalized Pustular
Psoriasis (GPP)
Phase 3 completed
Comprehensive data at
H2 2024 med meeting
Etokimab
(IL-33 antagonist)
Epithelial Driven
Diseases
P2b/3-ready
Out-license in 2024
No further internal investment
Legacy Programs Available for Outlicensing
Cytokine Antagonists
Imsidolimab
(IL-36R antagonist)
ANB032
(BTLA agonist)
Atopic Dermatitis
Top-line P2b data
December 2024
Immune Cell Modulators